FindTrial
Sign In

Rituximab treatment for patients with Wegener's granulomatosis

Rituximab treatment for patients with Wegener's granulomatosis - Rituximab treatment for Wegener's granulomatosis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000007076
Enrollment
5
Registered
2012-01-16
Start date
2011-01-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Wegener&#39

Interventions

Weekly infusion of rituximab 500 mg for 4 times

Sponsors

Kawasaki Medical School
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: The case of Wegener's granulomatosis resistant to standard therapy with cyclophosphamide

Exclusion criteria

Exclusion criteria: The case who is disqualified by the physician

Design outcomes

Primary

MeasureTime frame
complete remission at 12 months—

Secondary

MeasureTime frame
adverse events, BVAS/WG—

Countries

Japan

Contacts

Public ContactYoshitaka Morita

Kawasaki Medical School Department of Rheumatology

morita@med.kawasaki-m.ac.jp086-462-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026